COMMUNIQUÉS West-GlobeNewswire

SAB BIO to Participate in Upcoming Investor Conferences
31/01/2025
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti- [...]
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
31/01/2025
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual [...]
OKYO Pharma Announces Chairman and CEO Acquire Shares
31/01/2025
LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), [...]
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
31/01/2025
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
31/01/2025
First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in the first half of [...]
Director/PDMR Shareholding
31/01/2025
DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support [...]
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
31/01/2025
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study that demonstrated [...]
Communiqué de presse : Sarclisa est le premier anti-CD38 approuvé en Chine pour le traitement du myélome multiple nouvellement diagnostiqué des patients non éligibles à une greffe
31/01/2025
Sarclisa est le premier anti-CD38 approuvé en Chine pour le traitement du myélome multiple nouvellement diagnostiqué des patients non éligibles à une greffe Approbation motivée par les résultats positifs de l’étude de [...]
Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update
31/01/2025
Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today. Conference call [...]
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
30/01/2025
MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody [...]
Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine
30/01/2025
Diag-Nose.io, a CDL-Seattle graduate, harnesses AI with RhinoMAP™ to redefine respiratory care, securing $2M in oversubscribed funding SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- A groundbreaking precision medicine [...]
Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics
30/01/2025
Diag-Nose.io sets new standards in respiratory care with AI and proteomics after a $2M seed funding success, now expanding to Bethlehem, PA BETHLEHEM, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- A groundbreaking precision [...]
Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI
30/01/2025
Diag-Nose.io launches Houston office to advance precise respiratory care using AI and proteomics after a successful $2M seed round HOUSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Diag-Nose.io, a cutting-edge biotech company [...]
Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine
30/01/2025
Diag-Nose.io, a Stanford EENT Innovation graduate, secures $2M in oversubscribed seed funding to revolutionize respiratory care with precise, AI-driven diagnostics and treatment MENLO PARK, Calif., Jan. 30, 2025 (GLOBE [...]
Globus Medical Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
30/01/2025
AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31 [...]
Portage Biotech Announces Completion of $2.15 Million Private Financing
30/01/2025
DOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced [...]
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
30/01/2025
Conference call scheduled for 8:00 a.m. Eastern Time WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]
Conavi Medical Corp. Announces Proposed Public Offering of Units
30/01/2025
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“ Conavi Medical ” or the “ [...]
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
30/01/2025
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]

Pages